公开(公告)号：US10548942B2

公开(公告)日：2020-02-04

申请号：US15962067

申请日：2018-04-25

Applicant: STC.UNM

Inventor： Jeff Wade Hill

IPC: A61K38/06 ,  C07K5/097 ,  A61K38/00 ,  C07K14/715 ,  A61K45/06

Abstract: The present invention provides a novel class of medicament based on CXCR antagonistic peptides. Among other things, the present invention provides peptides, compositions and methods for treating diseases, disorders and conditions in which a CXCR mediated pathway is implicated. Compositions and methods for effective treatment of inflammation, stroke, traumatic brain injury, pancreatic cancer, and others are provided.

公开(公告)号：US20160296588A1

公开(公告)日：2016-10-13

申请号：US15038557

申请日：2014-11-25

Applicant: STC.UNM

Inventor： Jeff Wade Hill

IPC: A61K38/06 ,  A61K45/06 ,  A61K47/48

CPC classification number: A61K38/06 ,  A61K38/00 ,  A61K45/06 ,  C07K5/0823 ,  C07K14/7158

Abstract: The present invention provides a novel class of medicament based on CXCR antagonistic peptides. Among other things, the present invention provides peptides, compositions and methods for treating diseases, disorders and conditions in which a CXCR mediated pathway is implicated. Compositions and methods for effective treatment of inflammation, stroke, traumatic brain injury, pancreatic cancer, and others are provided.

Abstract translation: 本发明提供了一种基于CXCR拮抗肽的新型药物。 除其他之外，本发明提供用于治疗涉及CXCR介导的途径的疾病，病症和病症的肽，组合物和方法。 提供了有效治疗炎症，中风，创伤性脑损伤，胰腺癌等的组合物和方法。

公开(公告)号：US20180311302A1

公开(公告)日：2018-11-01

申请号：US15962067

申请日：2018-04-25

Applicant: STC.UNM

Inventor： Jeff Wade Hill

IPC: A61K38/06 ,  C07K14/715 ,  A61K45/06

CPC classification number: A61K38/06 ,  A61K38/00 ,  A61K45/06 ,  C07K5/0823 ,  C07K14/7158

Abstract: The present invention provides a novel class of medicament based on CXCR antagonistic peptides. Among other things, the present invention provides peptides, compositions and methods for treating diseases, disorders and conditions in which a CXCR mediated pathway is implicated. Compositions and methods for effective treatment of inflammation, stroke, traumatic brain injury, pancreatic cancer, and others are provided.

公开(公告)号：US09981003B2

公开(公告)日：2018-05-29

申请号：US15038557

申请日：2014-11-25

Applicant: STC.UNM

Inventor： Jeff Wade Hill

IPC: A61K38/06 ,  C07K5/097 ,  C07K14/715 ,  A61K45/06 ,  A61K38/00

CPC classification number: A61K38/06 ,  A61K38/00 ,  A61K45/06 ,  C07K5/0823 ,  C07K14/7158

Abstract: The present invention provides a novel class of medicament based on CXCR antagonistic peptides. Among other things, the present invention provides peptides, compositions and methods for treating diseases, disorders and conditions in which a CXCR mediated pathway is implicated. Compositions and methods for effective treatment of inflammation, stroke, traumatic brain injury, pancreatic cancer, and others are provided.

公开(公告)号：US10220008B2

公开(公告)日：2019-03-05

申请号：US14911943

申请日：2014-08-14

Applicant: STC.UNM

Inventor： Jeff Wade Hill

IPC: A61K31/138 ,  A61K9/00 ,  A61K31/27 ,  A61K31/325 ,  A61K45/06 ,  G01N33/50

Abstract: Using high-throughput screening, in an oxygen-glucose deprivation (OGD) model, isoxsuprine hydrochloride was identified as a potent neuroprotective compound. In an animal middle artery occlusion (MCAO) model of transient focal ischemia, isoxsuprine significantly reduced infarct volume compared to vehicle. The invention, therefore, provides methods of treatment and pharmaceutical compositions that are useful in the treatment and prevention of a wide-variety of ischemia-related injuries, including stroke.